



Correction to: Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies

Rodrigo Poubel Vieira de Rezende¹ · Evandro Mendes Klumb² · Gecilmara Salviato Pileggi³

Published online: 21 July 2020

© International League of Associations for Rheumatology (ILAR) 2020

Correction to: Clinical Rheumatology (2020) 39:1703–1705

<https://doi.org/10.1007/s10067-020-05039-x>

Table 2 in the original version of the above article was incorrectly presented. The data were misaligned during publication process. The correct Table 2 is shown as follows:

The online version of the original article can be found at <https://doi.org/10.1007/s10067-020-05039-x>

✉ Rodrigo Poubel Vieira de Rezende
ropoubel@id.uff.br

¹ Departamento de Medicina Clínica, Hospital Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense, Av. Marquês do Paraná, 303, Centro, Niterói, RJ 24030-210, Brazil

² Departamento de Reumatologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

³ Faculdade de Ciências da Saúde de Barretos (FACISB), Barretos, SP, Brazil

Table 2 Comparison of the frequency of mortality associated with all-cause pneumonia between adults aged ≥ 19 years with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignant neoplasms. Mortality data from the general population of the State of Rio de Janeiro, Brazil, 2006–2018

	PMN-associated deaths, <i>n</i> (AIRD group / comparator group)	non-PMN-associated deaths, <i>n</i> (AIRD group / comparator group)	Odds ratio (95% CI) ^a	<i>P</i> value
Disease groups, women				
CTD vs HIV	496 / 2227	1,250 / 5631	1.0 (0.89–1.12)	0.95
CTD vs malignant neoplasms	496 / 11,313	1,250 / 117,308	4.1 (3.70–4.57)	<0.0001
RA vs HIV	215 / 2227	261 / 5631	2.1 (1.72–2.51)	<0.0001
RA vs malignant neoplasms	215 / 11,313	261 / 117,308	8.5 (7.12–10.24)	<0.0001
Disease groups, men				
CTD vs HIV	102 / 3753	259 / 9858	1.0 (0.82–1.30)	0.77
CTD vs malignant neoplasms	102 / 13,812	259 / 114,236	3.3 (2.58–4.09)	<0.0001
RA vs HIV	58 / 3753	56 / 9858	2.7 (1.88–3.93)	<0.0001
RA vs malignant neoplasms	58 / 13,812	56 / 114,236	8.6 (5.93–12.37)	<0.0001

^a For between-group comparisons, the odds ratio formula is given by: (PMN-associated deaths in the CTD or RA group \times non-PMN-associated deaths in the HIV or malignant neoplasm group) \div (non-PMN-associated deaths in the CTD or RA group \times PMN-associated deaths in the HIV or malignant neoplasm group). This methodology has been previously applied in the assessment of mortality associated with the systemic connective tissue diseases [13]

AIRD autoimmune inflammatory rheumatic disease, CI confidence interval, CTD systemic connective tissue diseases, HIV human immunodeficiency virus, PMN all-cause pneumonia, RA rheumatoid arthritis

Reference

- Sartori Vieira C, de Rezende RPV, Mendes Klumb E, Cardoso Mocarzel LO, Altenburg Gismondi R (2019) Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. *Lupus* 28:1498–1500

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.